Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.067 AUD | +3.08% | -5.63% | -5.63% |
Feb. 27 | Noxopharm Narrows Fiscal H1 Net Loss Despite Lower R&D Tax Incentive | MT |
Feb. 26 | Noxopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
-5.63% | 12.39M | |
+0.44% | 90.27B | |
+10.00% | 44.05B | |
-16.82% | 31.45B | |
+44.30% | 23.35B | |
-8.60% | 16.72B | |
-25.64% | 15.09B | |
-9.33% | 12.82B | |
-7.57% | 11.95B | |
+0.07% | 8.71B |
- Stock
- Equities
- Stock Noxopharm Limited - Australian S.E.
- News Noxopharm Limited
- Noxopharm : Confirms Combination of Veyonda with LuPSMA Therapy Leads to Prostate Cancer Regression